Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP1LC3B | Q9GZQ8 | 7/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | LDHA | P00338 | 1/20 | 0.40 |
| ▸ | LDHB | P07195 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | AXL | P30530 | 1/20 | 0.40 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.40 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.40 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1779869 | 0.85 | MAP1LC3B (1.00) | MAP1LC3BHPGDALDH1A1POLBHTT | |
| SCHEMBL1780581 | 0.84 | MAP1LC3B (1.00) | MAP1LC3BALDH1A1POLBHTTSMN1; SMN2 | |
| SCHEMBL21821985 | 0.84 | MAP1LC3B (0.74) | MAP1LC3BHPGDALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL1780317 | 0.83 | MAP1LC3B (1.00) | MAP1LC3BALDH1A1HTTSMN1; SMN2KMT2A | |
| SCHEMBL21774003 | 0.81 | MAP1LC3B (0.70) | MAP1LC3BHPGDALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL21821935 | 0.81 | MAP1LC3B (0.68) | MAP1LC3BKMT2AMEN1 | |
| SCHEMBL29582480 | 0.81 | MAP1LC3B (0.68) | MAP1LC3BKMT2AMEN1 | |
| SCHEMBL21821964 | 0.81 | MAP1LC3B (0.71) | MAP1LC3BALDH1A1HTTSMN1; SMN2MAPK1 | |
| SCHEMBL21821722 | 0.80 | MAP1LC3B (0.71) | MAP1LC3BALDH1A1KMT2ACYP3A4CYP2D6 | |
| SCHEMBL21822025 | 0.77 | MAP1LC3B (0.63) | MAP1LC3BHPGDALDH1A1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023284420-A1 | APPLICATION OF POLYCYCLIC ARYL COMPOUND IN PREPARATION OF ANTIFUNGAL DRUG | 暨南大学附属第一医院 | 2023-01-19 | — | — | WO | disclosed |
| US-11529321-B2 | Use of aminomethylenecyclohexane-1,3-dione compound | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2022-12-20 | — | — | US | disclosed |
| US-20200170966-A1 | USE OF AMINOMETHYLENECYCLOHEXANE-1,3-DIONE COMPOUND | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2020-06-04 | — | — | US | disclosed |
| US-8592430-B2 | Quinazolin-oxime derivatives as Hsp90 inhibitors | DAC SLR (IT) | 2013-11-26 | — | — | US | disclosed |
| EP-2144889-B1 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC SRL (IT) | 2012-08-29 | — | — | EP | disclosed |
| EP-2144889-B1 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC SRL (IT) | 2012-08-29 | — | — | EP | disclosed |
| US-20110118258-A1 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC SRL (IT) | 2011-05-19 | — | — | US | disclosed |
| US-20110118258-A1 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC SRL (IT) | 2011-05-19 | — | — | US | disclosed |
| US-20110118258-A1 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC SRL (IT) | 2011-05-19 | — | — | US | disclosed |
| EP-2144889-A2 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC S.r.l. (IT) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008142720-A2 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC SRL (IT) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008142720-A2 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC SRL (IT) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118258-A1 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90B1 | MAP1LC3B 726/4885HPGD 886/4885ALDH1A1 1998/4885 |
| US-20200170966-A1 | USE OF AMINOMETHYLENECYCLOHEXANE-1,3-DIONE COMPOUND | ATG7, BECN1, SQSTM1 | MAP1LC3B 10/4885HPGD 2830/4885ALDH1A1 3815/4885 |
| US-11529321-B2 | Use of aminomethylenecyclohexane-1,3-dione compound | ATG7, BECN1, SQSTM1 | MAP1LC3B 10/4885HPGD 2830/4885ALDH1A1 3815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.